Telik, Inc. (Nasdaq: TELK) is a biopharmaceutical company dedicated to discovering, developing and commercializing novel small molecule drugs to treat cancer and other serious diseases. One development candidate is TELINTRA® (TLK199) which is currently in Phase 2 clinical development for myelodysplastic syndrome, and severe chronic idiopathic neutropenia.  TELINTRA® is also being evaluated for the treatment of additional blood disorders.  Another product candidate, TELCYTA® (TLK286), is a cancer cell-activated chemotherapeutic that has shown clinical activity in Phase 2 and Phase 3 clinical trials in advanced ovarian cancer, non-small cell lung cancer, colon cancer and breast cancer. These product candidates, and the other candidates in our pipeline, were discovered using our proprietary technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.

Investor Info

2011 Annual Report

2012 Proxy Statement

Latest News

May 15 , 2012
Telik Announces the Publication of Two Reports in the Journal Of Hematology & Oncology Describing the Results of a Clinical Study of Telintra® in Combination With Revlimid® and a Genomic Study Designed to Identify Genes That Predict Response to Telintra in Patients With Myelodysplastic Syndrome

May 09 , 2012
Telik Announces First Quarter 2012 Financial Results

April 17 , 2012
Telik Regains Compliance with Minimum Bid Price Requirement

 

 

 

 

 

 

 

Sitemap Contact Legal Notice Telik Home